List of Excipients in Branded Drug CHLORHEXIDINE GLUCONANTE

Generic Drugs Containing CHLORHEXIDINE GLUCONANTE

Company	Ingredient	NDC	Excipient
AMD Medicom Inc	chlorhexidine gluconante	64778-0244	ALCOHOL
AMD Medicom Inc	chlorhexidine gluconante	64778-0244	FD&C BLUE NO. 1
AMD Medicom Inc	chlorhexidine gluconante	64778-0244	GLYCERIN

What are the Most Frequently-Used Excipients in CHLORHEXIDINE GLUCONANTE?

# Of NDCs	Excipient
1	ALCOHOL
1	FD&C BLUE NO. 1
1	GLYCERIN

Chlorhexidine Gluconate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Chlorhexidine gluconate (CHG) is an established cationic antiseptic with limited opportunity for new-molecule exclusivity. Commercial value is concentrated in formulation engineering, delivery systems, manufacturing controls, regulatory positioning, and differentiated use settings. The strongest opportunities are alcohol-free skin antiseptics, dental products, catheter and device coatings, low-residue formulations, and packaging systems that improve safety and usability.

What is the commercial status of chlorhexidine gluconate?

Chlorhexidine gluconate is widely used in oral rinses, surgical skin preparations, wound-care products, catheter dressings, medical-device coatings, and veterinary antiseptics. It is supplied as a gluconate salt because the salt form is water-soluble and practical for aqueous formulations.

Attribute	Commercial assessment
Active ingredient	Chlorhexidine gluconate
Pharmacologic class	Cationic bisbiguanide antiseptic
Main routes	Topical, oral rinse, mucosal and device-associated delivery
Common concentrations	Approximately 0.05% to 4% CHG, depending on use
Oral-rinse concentration	Commonly 0.12%
Surgical skin-prep concentration	Commonly 2% CHG with alcohol
High-strength cleanser	Commonly 4% CHG
Basic active-ingredient exclusivity	Expired or commercially unavailable as a barrier in most jurisdictions
Main barriers today	Formulation know-how, compatibility, device integration, clinical data, manufacturing validation and regulatory compliance
Primary competitors	Povidone-iodine, alcohol-only products, benzalkonium chloride, octenidine, hydrogen peroxide and silver-based products

CHG’s cationic mechanism produces broad activity against many Gram-positive and Gram-negative bacteria. Its persistent substantivity on skin and oral surfaces supports use in surgical preparation and dental care. The same cationic chemistry creates excipient-compatibility constraints that can limit formulation flexibility [1, 2].

Which excipients are most important in chlorhexidine gluconate formulations?

The excipient strategy should begin with compatibility screening rather than conventional preservative selection. Anionic ingredients can bind or neutralize CHG and reduce antimicrobial performance.

Core excipient categories

Excipient category	Typical role	Strategic considerations
Purified water	Vehicle	Ionic content, microbial quality and container interaction require control
Alcohols	Rapid drying and enhanced antimicrobial activity	Ethanol and isopropanol support fast-drying skin products but increase flammability and irritation
Humectants	Reduce drying and improve mouthfeel	Glycerin and sorbitol are useful in oral products but can affect viscosity and residual feel
Polyethylene glycols	Solubilization and texture	Molecular weight and concentration can affect clarity and deposition
Nonionic surfactants	Wetting and soil removal	Generally more compatible than anionic surfactants, but each grade requires testing
Thickeners	Improve residence time	Hydroxyethyl cellulose and selected nonionic polymers can support gels and mucosal products
Flavor systems	Oral acceptability	Essential oils and aromatic compounds can affect CHG availability and staining
Sweeteners	Taste masking	Sodium saccharin is common in oral products; sugar-containing systems create dental and microbial considerations
Chelators	Metal-ion control	Useful in some systems but require compatibility and regulatory review
Buffers	pH control	Buffer selection must avoid precipitation, potency loss and irritation
Preservatives	Microbial protection	CHG itself is antimicrobial, but preservation may still be required for multidose systems

The formulation target is usually a clear, stable system with controlled pH, low particulate burden, validated antimicrobial activity and minimal interaction with the package or applicator.

Why anionic excipients create a technical barrier

CHG is positively charged. Anionic surfactants, soaps, some polymers, certain dyes and other negatively charged materials can form complexes with CHG. This can cause precipitation, haze, adsorption, potency loss or reduced microbiological activity.

Formulators should treat the following as high-risk categories:

• Soaps and fatty-acid salts
• Sodium lauryl sulfate and related anionic surfactants
• Carboxylated or strongly anionic polymers
• Some phosphate-containing systems
• Certain anionic dyes
• Materials with high levels of free chloride or other reactive ions
• Residues from cleaning agents used in manufacturing

Compatibility must be assessed in the finished formulation, not inferred from ingredient class alone. Concentration, pH, ionic strength, temperature, order of addition and container contact can change performance.

What formulations are protected by chlorhexidine gluconate excipient strategy?

The most defensible formulation opportunities are products in which excipients solve a defined clinical or operational problem.

Alcohol-free skin antiseptics

Alcohol-based CHG products dominate rapid preoperative preparation because alcohol provides fast kill and drying. Alcohol-free systems can target:

• Neonatal and pediatric use
• Sensitive skin
• Repeated application
• Mucosal or perineal areas
• Facilities with flammability restrictions
• Home-care and nursing applications

The principal technical challenge is matching the speed of alcohol-containing products without increasing residue, irritation or drying time. A differentiated product may use a carefully selected nonionic surfactant, humectant and film-forming polymer to improve coverage and persistence.

Low-residue and low-staining oral rinses

CHG oral rinses are effective but can cause tooth staining, taste disturbance, oral irritation and calculus formation with extended use [3]. Excipients can support commercial differentiation through:

• Reduced flavor intensity
• Improved taste masking
• Lower residue
• Alcohol-free delivery
• Unit-dose packaging
• Reduced staining through shorter treatment courses or optimized contact time

A formulation cannot claim reduced staining solely from excipient selection without clinical evidence. However, better flavor systems and reduced surface deposition may improve adherence.

Mucoadhesive gels

A CHG gel can extend contact time on oral, vaginal or wound surfaces. The opportunity depends on selecting polymers that do not bind or inactivate the cationic active. Candidate systems should be screened for:

• CHG release rate
• Viscosity over shelf life
• Adhesion under wet conditions
• Ease of rinsing or removal
• Irritation
• Sterilization compatibility
• Microbial stability

Mucoadhesive polymers may create a stronger patent position than a simple aqueous CHG product because the claims can cover composition ranges, release profiles, application frequency and treatment indications.

Foams, wipes and premoistened applicators

Premoistened wipes and foams can reduce preparation time and improve dosing consistency. Commercial differentiation may come from:

• Low-lint substrates
• Controlled liquid loading
• Single-use packaging
• Reduced dripping
• Applicator geometry
• Defined coverage area
• Compatibility with gloves and medical devices

The substrate is part of the product’s performance. Cellulose, rayon, polypropylene and blended nonwovens can adsorb CHG differently. The formulation should be tested after contact with the final substrate, because measured concentration in the bulk liquid may not reflect delivered dose.

How does chlorhexidine gluconate compare with competing antiseptics?

Attribute	CHG	Povidone-iodine	Alcohol-only	Benzalkonium chloride
Skin persistence	High	Lower	Low	Moderate
Drying speed	Moderate alone; high with alcohol	Slow to moderate	High	Moderate
Broad activity	Strong against many bacteria	Broad	Broad but limited persistence	Narrower than CHG in some settings
Formulation sensitivity	High because of cationic chemistry	Iodine stability and staining concerns	Flammability and drying	Compatibility and resistance concerns
Oral use	Established in prescription rinses	Limited by taste and staining	Generally unsuitable for routine oral antisepsis	Limited use
Main commercial weakness	Irritation, allergy, staining and incompatibility	Staining, irritation and tissue limitations	No residual activity	Lower persistence and narrower positioning

CHG has a strong position where persistence matters. Povidone-iodine remains important where broad-spectrum activity, low cost or established surgical protocols outweigh persistence. Alcohol-only products compete on speed and simplicity. Product selection depends on procedure, site, patient population and institutional protocol [4].

What is the FDA regulatory status of chlorhexidine gluconate products?

FDA status depends on the product category, concentration, route and claims. CHG products include approved prescription drug products, over-the-counter antiseptic products, medical-device-associated products and combination products.

A prominent prescription oral-rinse category is chlorhexidine gluconate 0.12% oral rinse. The FDA labeling for Peridex identifies oral-rinse use, inactive ingredients and warnings concerning staining, taste alteration, hypersensitivity and accidental ingestion [5].

Surgical skin-preparation products often combine CHG with isopropyl alcohol or ethanol. The regulatory package must address flammability, application technique, drying time, pooling, neonatal use, ophthalmic exposure and ototoxicity risk. A device applicator may be regulated with the drug as a combination product or under a device-linked pathway, depending on the product design and claims.

What does the Orange Book status mean for CHG?

The Orange Book is relevant to approved drug products, particularly prescription oral rinses and other listed formulations. It does not provide a complete view of every CHG commercial product because many topical antiseptic products are marketed under different regulatory frameworks.

For a specific CHG product, the relevant review should cover:

1. Listed patents and regulatory exclusivity in the Orange Book.
2. Approved labeling and dosage form.
3. Patent expiration and pediatric exclusivity, if any.
4. Abbreviated new drug application pathways.
5. Product-specific litigation and Paragraph IV certifications.
6. Whether the relevant formulation is marketed as a drug, device, or combination product.

The active ingredient’s age means that commercial protection is more likely to arise from product-specific formulation, applicator, coating, manufacturing or method-of-use claims than from basic composition-of-matter claims.

When does chlorhexidine gluconate lose exclusivity?

Basic CHG exclusivity has largely expired because the compound has been used commercially for decades. There is no single worldwide expiration date for "chlorhexidine gluconate." Exclusivity must be analyzed by product and jurisdiction.

Protection type	Likely status for CHG	Commercial effect
Composition of matter	Historical and generally expired	Does not block ordinary CHG manufacture
Basic aqueous formulation	Often vulnerable to competition	Supports generic or private-label entry
Specific oral-rinse formulation	May have product-specific patents or regulatory protection	Can delay equivalent entry
Alcohol-CHG skin preparation	Potential formulation, packaging or applicator claims	Can protect differentiated products
Device coating	Potential composition, coating and manufacturing claims	May create stronger technical barriers
Manufacturing process	Possible process protection	More relevant where purity, particle control or coating quality matters
Method of use	Possible indication- or population-specific protection	Depends on claim scope and clinical evidence

A patent search should be performed by jurisdiction, assignee, product, dosage form and claim category. Searching only "chlorhexidine gluconate" will miss patents that claim a device coating, applicator, substrate, antimicrobial composition or treatment method.

Which companies are challenging chlorhexidine gluconate products?

Competition is fragmented rather than concentrated in a single branded challenger. Relevant participants include:

• Dental manufacturers selling CHG oral rinses and professional products
• Surgical antiseptic companies selling CHG-alcohol preparations
• Generic drug manufacturers
• Private-label topical antiseptic suppliers
• Medical-device companies selling antimicrobial catheter and dressing systems
• Contract manufacturers producing wipes, gels, solutions and foams

For mature CHG products, competitive entry typically occurs through ANDA approval, OTC monograph positioning, private-label supply, hospital contracting or combination-product development. Litigation risk is usually product-specific. A Paragraph IV challenge may matter for a branded prescription oral rinse, but it does not establish freedom to market a different CHG topical product.

What patent litigation and settlement risks affect CHG products?

The highest litigation risk is associated with differentiated commercial products, not the old active ingredient. Key risk areas include:

• Orange Book-listed patents for prescription oral rinses
• Patents covering CHG-alcohol ratios and drying performance
• Applicator design and controlled-dose delivery
• Antimicrobial catheter and dressing coatings
• Sustained-release or mucoadhesive formulations
• Manufacturing methods for coated substrates
• Claims directed to neonatal, surgical or device-associated use

Settlement agreements involving a branded CHG product may contain license dates, authorized-generic provisions, supply arrangements or restrictions on launch timing. These terms should be reviewed in the applicable court docket and FDA records rather than inferred from the existence of a generic product.

How strong is the patent estate for a new chlorhexidine gluconate product?

Patent strength depends on whether the product has a measurable technical distinction.

Product concept	Patent strength potential	Main weakness
Generic aqueous CHG solution	Low	Easy to design around
CHG mouthwash with improved taste	Low to moderate	Clinical benefit may be difficult to prove
Alcohol-free high-persistence skin formulation	Moderate	Requires comparative data
CHG-loaded wipe with controlled delivery	Moderate	Substrate and loading claims may be narrow
Sustained-release oral or mucosal gel	Moderate to high	Requires release and clinical evidence
CHG catheter coating	High relative to ordinary solutions	Manufacturing and coating reproducibility are barriers
Single-use applicator with controlled coverage	Moderate	Design-around risk
Pediatric or neonatal formulation	Moderate	Safety and regulatory requirements are demanding

The strongest portfolio typically combines composition claims with method, device, manufacturing and packaging claims. A single broad formulation claim is more vulnerable to invalidity or design-around strategies.

What manufacturing and IP barriers exist?

Manufacturing controls can become commercial barriers even when patents are weak. Key controls include:

• Accurate CHG assay and impurity profiling
• Control of pH and ionic strength
• Prevention of precipitation
• Low-bioburden or sterile processing where required
• Compatibility of pumps, caps, tubes and applicators
• Uniform loading of wipes and coated devices
• Stability under heat and freeze-thaw conditions
• Container-closure integrity
• Control of alcohol evaporation
• Cleaning validation to prevent anionic residue

For device coatings, the critical parameters are coating uniformity, release kinetics, substrate adhesion, sterilization stability and retained antimicrobial activity. These factors can support trade-secret protection even when patent claims are limited.

What commercial opportunities have the highest value?

The most attractive opportunities are:

1. Alcohol-free CHG products for sensitive-skin and repeated-use populations.
2. Low-stain, low-taste oral rinses supported by adherence and tolerability data.
3. Single-use applicators with dose and coverage control.
4. CHG-loaded wipes and foams for home-care and institutional workflows.
5. Sustained-release oral, mucosal or wound formulations.
6. Antimicrobial catheter, dressing and surgical-device coatings.
7. Pediatric and neonatal products with validated safety profiles.
8. Contract manufacturing platforms for CHG products with difficult compatibility requirements.

Revenue exposure is generally higher in hospital skin preparation and device-associated products than in undifferentiated consumer antiseptic liquids. Pricing power is strongest where the product reduces procedure time, improves dosing consistency, limits contamination or integrates with an established clinical workflow.

Key Takeaways

• Chlorhexidine gluconate is a mature, largely off-patent active ingredient.
• Commercial protection now depends on formulation, delivery system, device integration, manufacturing and clinical positioning.
• Cationic chemistry makes compatibility with anionic excipients a central development risk.
• Alcohol-free, low-residue, mucoadhesive, controlled-dose and device-integrated products offer the clearest differentiation.
• Orange Book, Paragraph IV and litigation analysis must be performed at the individual product level.
• The strongest patent strategy combines composition, method-of-use, applicator, manufacturing and packaging claims.
• The largest commercial barriers may be technical validation and regulatory execution rather than basic active-ingredient patent rights.

FAQs About Chlorhexidine Gluconate Formulation and Commercialization

Can chlorhexidine gluconate be formulated with sodium lauryl sulfate?

It is generally a high-risk combination because sodium lauryl sulfate is an anionic surfactant that can interact with cationic CHG. Any proposed combination requires direct potency, precipitation and antimicrobial-activity testing.

Is alcohol necessary for an effective chlorhexidine gluconate skin product?

No. Alcohol improves rapid kill and drying, but alcohol-free CHG systems can be developed. They require optimization of concentration, contact time, wetting, persistence and user acceptability.

Which dosage form offers the best opportunity for CHG lifecycle management?

Sustained-release gels, controlled-dose applicators, antimicrobial device coatings and substrate-engineered wipes generally offer stronger lifecycle-management potential than conventional aqueous solutions.

Can chlorhexidine gluconate be used in ophthalmic products?

CHG is not suitable for routine ocular exposure and can cause serious eye injury. Products intended for skin or mucosal use require strict labeling, packaging and application controls to prevent ocular contact [5].

Does a new CHG excipient combination automatically receive patent protection?

No. Patentability requires novelty, inventive step or nonobviousness, and adequate disclosure. The combination also needs a credible technical effect, such as improved stability, release, delivery, tolerability or antimicrobial performance.

References

1. McDonnell, G., & Russell, A. D. (1999). Antiseptics and disinfectants: Activity, action, and resistance. Clinical Microbiology Reviews, 12(1), 147-179.

2. Russell, A. D. (2000). Chlorhexidine: Antibacterial action and bacterial resistance. Infection, 28(Suppl. 1), 3-8.

3. James, P., Worthington, H. V., Parnell, C., Harding, M., Lamont, T., Cheung, A., & Beirne, P. V. (2017). Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database of Systematic Reviews, 3, CD008676.

4. World Health Organization. (2016). Global guidelines for the prevention of surgical site infection. World Health Organization.

5. U.S. Food and Drug Administration. (n.d.). Peridex chlorhexidine gluconate oral rinse prescribing information. DailyMed.